Fig 2: RMI2 expression in HCC patients.

Fig 3: RMI2 protein expression in our clinical breast cancer patients. (A) Negative RMI2 expression in normal tissue (×100, ×400). (B) Negative RMI2 expression in breast cancer tissue (×100, ×400). (C) Moderate RMI2 expression in breast cancer tissue (×100, ×400). (D) Strongly positive RMI2 expression in breast cancer tissue (×100, ×400). (E) The expression of RMI2 protein in breast cancer tissues was higher than that in normal tissues (p < 0.0001). (F) The expression of RMI2 protein in stages I‐III was statistically significant compared with the normal group in our study (all p < 0.0001). (G) ROC curve showing the diagnostic value of RMI2 for breast cancer.

Fig 4: The expression levels of RMI2 in public databases. (A) Expression of RMI2 in different types of tumors in TCGA and GTEx databases. (B) Expression of RMI2 in paired tumor and normal tissues in the TCGA database. Expression levels of RMI2 in nonpaired breast cancer tissues and normal tissues (C) as well as paired samples (D). (E) RMI2 was upregulated in breast cancer tissues compared to normal tissues in multiple datasets except GSE73235 in the GEO database. The ordinate is the datasets, the abscissa is log2 (Fold Change), and the point size represents significance (indicated by the inverse log10 of p values). *p < 0.05, **p < 0.01, ***p < 0.001.

Fig 5: Relationships between RMI2 and proliferation and EMT in breast cancer samples from TCGA. (A, B) Pearson's correlation between RMI2 and proliferation‐related genes, including MKI67 (r = 0.51), PCNA (r = 0.66), MCM2 (r = 0.64), MCM3 (r = 0.61), MCM4 (r = 0.51), and MCM6 (r = 0.60). (C, D) Pearson's correlation between RMI2 and EMT‐related genes including CTNNB1 (r = −0.19), TJP1 (r = −0.24), and MMP9 (r = 0.14). ***p < 0.001.